Evaluation of MEDI5752 in Patients with Advanced Solid Tumors: A Clinical Trial

The primary objective of this study is to evaluate the efficacy and safety of **MEDI5752** in subjects with **advanced solid tumors**. This is clinically relevant as advanced solid tumors often present significant treatment challenges, and new therapeutic options are needed to improve patient outcomes. The study aims to assess the potential of MEDI5752 to provide clinical benefits in this patient population.

The clinical trial involves a total of **220 participants** diagnosed with **advanced solid tumors**. The study population includes both male and female subjects, encompassing an **age range** that includes adults and older adults. Participants were selected to ensure a diverse representation of the general population, including vulnerable groups. The trial does not specify particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective or specific inclusion criteria for the study.

The clinical trial is designed to evaluate the investigational product **MEDI5752** in subjects with **advanced solid tumors**. This study is a Phase 1 trial, which is typically focused on assessing the safety, tolerability, and pharmacokinetics of the investigational product. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from the recruitment start date on April 24, 2018, to the anticipated end date on April 29, 2025.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a comprehensive assessment, including medical history, physical examination, and laboratory tests. Following successful screening, participants will be randomized to receive either the investigational product or a control. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' health status, assess the investigational product's effects, and collect data on any adverse events. These visits are crucial for ensuring participant safety and evaluating the trial's endpoints.

The end-of-study visit will occur after the completion of the treatment period, where final assessments will be conducted to gather comprehensive data on the investigational product's impact. The expected length of participant involvement in the trial will vary depending on individual response and the study's progression. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed necessary by the investigator. The trial's design and procedures are structured to maintain scientific rigor while prioritizing participant safety and data integrity.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of this data precludes a comprehensive description of the treatments used in the study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to conclude by April 29, 2025, with recruitment having commenced on April 24, 2018. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize various parameters such as biomarker levels, symptom improvement scores, or other relevant clinical measures to evaluate efficacy. These parameters are typically measured at predefined intervals throughout the trial to monitor changes and assess the potential therapeutic effects of the investigational product. The data collected will be analyzed using appropriate statistical methods to determine the efficacy of the treatment under investigation. The trial's design and methodology adhere to regulatory standards to ensure the reliability and validity of the efficacy assessments.